Evidence map›Paper›PMID 31702856›Full record

ArticleAngewandte Chemie (International ed. in English)2020

Discovery of a Cryptic Intermediate in Late Steps of Mithramycin Biosynthesis.

Ryan Wheeler, Xia Yu, Caixia Hou, Prithiba Mitra, Jhong-Min Chen, Frank Herkules, Dmitri N Ivanov, Oleg V Tsodikov, Jürgen Rohr

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 18 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Ryan WheelerDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536-0596, USA.
Xia YuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536-0596, USA.
Caixia HouDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536-0596, USA.
Prithiba MitraDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536-0596, USA.
Jhong-Min ChenDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536-0596, USA.
Frank HerkulesDepartment of Biochemistry, University of Texas Health Science Center, San Antonio, TX, 78229, USA.
Dmitri N IvanovDepartment of Biochemistry, University of Texas Health Science Center, San Antonio, TX, 78229, USA.
Oleg V TsodikovDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536-0596, USA.ORCID 0000-0001-7094-4216
Jürgen RohrDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536-0596, USA.ORCID 0000-0001-6447-5951
University of Kentucky · USThe University of Texas Health Science Center at San Antonio · USCentral South University · CN

Funding

NOVEL AUREOLIC ACID TYPE ANTITUMOR AGENTSR01CA091901 · NCI · UNIVERSITY OF KENTUCKY · PI ROHR, JURGEN T · 2001 to 2017
$3.6M
Biochemistry of SAMHD1-mediated innate immunity responsesR01AI136697 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI IVANOV, DMITRI N · 2019 to 2022
$1.9M
Biochemistry of SAMHD1-mediated innate immunity responsesR37AI136697 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DMITRI N IVANOV · 2024 to 2026
$1.7M
BIOSYNTHETIC KEY STEPS OF ANGUCYCLINE ANTITUMOR DRUGSR01CA102102 · NCI · UNIVERSITY OF KENTUCKY · PI ROHR, JURGEN T · 2005 to 2009
$1.3M
Exploring Post-Type II PKS Frame ModificationsR01GM105977 · NIGMS · UNIVERSITY OF KENTUCKY · PI ROHR, JURGEN T · 2014 to 2017
$1.1M
NCI NIH HHS R01 CA091901NCI NIH HHS R01 CA102102NIAID NIH HHS R37 AI136697NIGMS NIH HHS R01 GM105977
6 · The paper itself

Abstract

MtmOIV and MtmW catalyze the final two reactions in the mithramycin (MTM) biosynthetic pathway, the Baeyer-Villiger opening of the fourth ring of premithramycin B (PMB), creating the C3 pentyl side chain, strictly followed by reduction of the distal keto group on the new side chain. Unexpectedly this results in a C2 stereoisomer of mithramycin, iso-mithramycin (iso-MTM). Iso-MTM undergoes a non-enzymatic isomerization to MTM catalyzed by Mg

Indexed as

Biological ProductsCatalysisPlicamycinBiological ProductsPlicamycinbiocatalysisbiosynthesisisomerizationnatural productsprotein structures

Identifiers

PMID31702856
PMCPMC6940538
OpenAlexW2989013417

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.